# Hormone Therapy May Boost Weight Loss on Wegovy, But Not on Zepbound
Adding hormone replacement therapy to GLP-1 medications produces different results depending on which weight loss drug someone takes. Women on Wegovy lost more weight when combining the injectable with hormone therapy, while those using Zepbound saw minimal additional benefit.
The distinction matters because both drugs contain the same active ingredient, semaglutide, yet perform differently when paired with hormonal treatment. This finding suggests that how the body metabolizes these medications interacts with hormone status in complex ways that researchers are still working to understand.
Researchers compared outcomes in women using either Wegovy or Zepbound alongside hormone replacement therapy containing estrogen and progesterone. The Wegovy group experienced greater weight loss reductions when adding hormones to their regimen. The Zepbound cohort, however, showed only marginal improvements. Experts attribute the gap to differences in how each drug formulates and delivers semaglutide, even though the core component remains identical.
Wegovy delivers semaglutide through a once-weekly injection, while Zepbound uses the same weekly injection format. The real variance lies in how each medication's manufacturing process and delivery system interacts with hormonal pathways in the body. Some research indicates that estrogen can influence appetite regulation and metabolic rate through effects on the hypothalamus and other brain regions that control hunger signals.
Dr. Angela Fitch, medical director at the Massachusetts General Hospital Weight Center, notes that hormone status influences how effectively GLP-1 drugs work. "We're seeing that the relationship between sex hormones and GLP-1 receptor activity isn't straightforward," Fitch explained in related commentary. Hormones affect not just appetite but also how quickly the stomach empties and how the body processes nutrients.
The findings carry practical implications for women considering weight loss medication. Those already taking hormone replacement therapy should understand that adding Wegovy might produce better results than Zepbound for weight reduction purposes. However, individual responses vary widely. Factors like age, metabolic rate, existing health conditions, and dosage all influence outcomes.
For women not currently on hormone therapy, the decision to add it specifically to enhance weight loss medication remains more complex. Hormone replacement therapy carries its own considerations, including slightly increased risks of blood clots and breast cancer in some populations. Any decision to start hormones should involve careful discussion with a healthcare provider weighing personal risk factors.
The research underscores an emerging truth in obesity treatment: one-size-fits-all approaches fail. GLP-1 medications work remarkably well for many people, but response rates vary substantially. Adding hormonal factors to the equation creates another layer of variability that treatment plans must account for.
Researchers continue studying how sex hormones modulate GLP-1 receptor function and metabolic pathways. Future work will likely refine guidance on which medication combinations work best for different populations. This personalized approach to weight loss treatment reflects a broader shift toward precision medicine, where individual biology guides therapeutic choices rather than generic protocols.
Women considering either Wegovy or Zepbound should discuss their complete medical history with their provider, including current or past hormone therapy use. The choice between medications may depend partly on whether hormone replacement fits their overall health plan.